IMMP Company Profile and Key Details

Q: Who are the executives of IMMP?

Ms. Deanne Miller LLBChief Operating Officer, Gen. Counsel & Joint Company Sec.Mr. Christian MuellerDirector of Clinical Devel. & Regulatory AffairsMr. Shengfei FangFin. Director & Assistant Company Sec.Mr. Marc VoigtChief Executive Officer, MD, Chief Financial Officer, Chief Bus. Officer & Executive DirectorMs. Indira NaiduJoint Company Sec.Mr. Florian D. Vogl M.D., M.Sc., Ph.D.Chief Medical OfficerDr. Frederic Triebel M.D., Ph.D.Chief Scientific Officer & Executive Director

NASDAQ : IMMP

Immutep

$2.79

-0.01-0.36%

At Close 4:00 PM

58.63

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Immutep Limited (IMMP) stock declined over -0.36%, trading at $2.79 on NASDAQ, down from the previous close of $2.80. The stock opened at $2.82, fluctuating between $2.77 and $2.83 in the recent session.

Stock Snapshot

2.8

Prev. Close

410.67M

Market Cap

2.77

Day Low

-6.64

P/E Ratio

-0.42

EPS (TTM)

-0.03

Cash Flow per Share

2.82

Open

147.19M

Number of Shares

2.8331

Day High

99.16%

Free Float in %

0.1

Book Value

110.88K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Feb 25, 2026	2.80	2.83	2.77	2.79	111.19K
Feb 24, 2026	2.85	2.85	2.72	2.80	137.55K
Feb 23, 2026	2.79	2.97	2.79	2.88	344.12K
Feb 20, 2026	2.86	2.93	2.78	2.79	63.35K
Feb 19, 2026	2.77	2.86	2.75	2.86	82.73K
Feb 18, 2026	2.77	2.83	2.77	2.80	108.03K
Feb 17, 2026	2.65	2.79	2.63	2.77	125.85K
Feb 13, 2026	2.70	2.74	2.64	2.64	143.29K
Feb 12, 2026	2.80	2.80	2.69	2.74	92.83K
Feb 11, 2026	2.76	2.83	2.68	2.79	102.31K
Feb 10, 2026	2.71	2.81	2.66	2.78	164.95K
Feb 09, 2026	2.60	2.76	2.60	2.73	122.65K
Feb 06, 2026	2.65	2.68	2.56	2.62	156.48K
Feb 05, 2026	2.68	2.71	2.61	2.62	109.93K
Feb 04, 2026	2.83	2.83	2.64	2.70	174.91K
Feb 03, 2026	2.86	2.86	2.75	2.83	171.79K
Feb 02, 2026	2.72	2.92	2.72	2.86	147.29K
Jan 30, 2026	2.97	2.97	2.69	2.73	385.3K
Jan 29, 2026	3.04	3.07	2.93	2.97	209.38K
Jan 28, 2026	3.10	3.10	3.01	3.06	183.82K

Contact Details

Sydney, NSW 2000

Australia

https://www.immutep.com 612 831 57003

About Company

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Stock Peers

ARGX

-23.33-2.78%

argenx SE$816.95 REGN

12.09+1.57%

Regeneron Pharmaceuticals, Inc.$784.28 UTHR

61.67+13.03%

United Therapeutics Corporation$535.10 VRTX

-4.38-0.90%

Vertex Pharmaceuticals Incorporated$483.05 MDGL

-4.99-1.13%

Madrigal Pharmaceuticals, Inc.$435.01 PRAX

4.84+1.41%

Praxis Precision Medicines, Inc.$347.55 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.49-1.65%

Alnylam Pharmaceuticals, Inc.$327.36 KRYS

5.6+2.10%

Krystal Biotech, Inc.$272.50 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Immutep Limited (NASDAQ:IMMP) closed at $2.79 USD, losing -$0.01 (-0.36%) from the previous close of $2.80. The stock is currently mid-range between its 52-week high and low $1.32 and $3.53. With a market capitalization of about $410.67 million, Immutep Limited is classified as a small-cap and shows higher-than-market volatility (beta ~1.69). Key stats such as the average daily volume over the past year has been around 739.72 thousand shares, volume is running light vs its 52-week average. Headquartered in Sydney, NSW, Immutep Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Marc Voigt, the company employs approximately 41 people and listed since April 19, 2012. Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 0.07%, SMA50 -2.39%, SMA200 34.9%). The stock’s 14-day RSI is 49.25 (neutral), while the ATR of 0.14 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -20.96% below its high and over 111.36% above its low. Average 10-day trading volume of 138.97 thousand shares is below the 3-month average of 738.86 thousand, indicating normal recent market interest.

Valuation Metrics

Immutep Limited trades at a P/E ratio of -9.33, slightly below the S&P 500 average, with a price-to-sales ratio of 114.69 and a price-to-book ratio of 3.99 trading at moderately above to book value. The P/FCF stands at -9.32, also above market averages.

Dividend & Fair Value

Immutep Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.09. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Immutep Limited generated EPS of -$0.27 over the past year. Five-year average earnings growth is -4.46%. Wall Street analysts project EPS growth of -2.87% annually over the next five years. The latest quarter delivered EPS of -$0.18. The next quarter is forecast at -$0.19. Next year's EPS is expected at -$21.12. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $6.00. The high target offers 258.42% upside. The low target suggests 115.05% downside. The mean target is $8.00. This offers 186.74% upside. Immutep Limited earnings surprise history is a mixed track record. The quarter that ended August 28, 2025, missed forecasts by 44.02%. The prior quarter beat by -88.73%. Over the last six quarters, Apple has recorded several small beats. These include 5.56% in February 22, 2021.

Shareholding & Insider Activity

Immutep Limited has 145.56 million shares outstanding. The public float is 1.22 billion shares, elevated short interest at 2.91% of float. This equals 4.16 million shares. The short ratio is 56.63 days. Institutional investors hold 1.91% of the float. Insiders own 0.01%.

Financial & Profitability Overview

Over the trailing twelve months, Immutep generated $5.04M in revenue, or $0.00 per share. Gross margin was -1117.55%, operating margin -2506.49%, and net profit margin -1218.02%. Returns are negative, with ROA at -39.13% and ROE at -42.77%.
On valuation metrics, Immutep trades at a P/E of -9.33, P/S of 114.69 and P/B of 3.99. The current ratio is 11.69 and quick ratio is 11.69. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -32.35 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -38.18.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, Immutep posted revenue of $5.04M, down slightly from $3.84M in the prior quarter. Gross profit was - $56.37M (margin -1117.55%). Operating income was - $126.42M (margin -2506.5%). Net income was- $61.43M (EPS - $0.04).
The company ended the quarter with $129.69M in cash and short-term investments, a total debt of $1.63M, and net debt of - $65.78M. Total assets were $156.98M, with equity of $143.64M. Financials further reflected weakness, with operating cash flow of - $62.05M, free cash flow of - $62.10M, and capital expenditures of - $45.77K.

Price Forecast & Outlook

Our AI price prediction model suggests that Immutep Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.23%, with price expected at $2.70 by March 11, 2026, within a range of $2.55 to $2.83 3-Month Outlook: Projected rise of 51.25%, reaching $4.22 by May 26, 2026, with a range of $4.15 to $4.30. 1-Year Outlook: Projected gain of 883.15%, with price at $27.43 by February 25, 2027, within a range of $27.89 to $29.00.

Key Takeaways

Immutep Limited (NASDAQ:IMMP) shares are flat -1.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Immutep Limited trading at a premium to the broader market with a P/E of -9.33. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $7.42, suggesting 165.95% upside. Our AI forecast model points to short-term weakness (-3.23% over two weeks), a medium-term rise (51.25% over three months), and a longer-term gain (883.15% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Immutep Limited (IMMP) stock price?

Immutep Limited (NASDAQ: IMMP) stock price is $2.79 in the last trading session. During the trading session, IMMP stock reached the peak price of $2.83 while $2.77 was the lowest point it dropped to. The percentage change in IMMP stock occurred in the recent session was -0.36% while the dollar amount for the price change in IMMP stock was - $0.01.

IMMP's industry and sector of operation?

The NASDAQ listed IMMP is part of Biotechnology industry that operates in the broader Healthcare sector. Immutep Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of IMMP?

Ms. Deanne Miller LLB
Chief Operating Officer, Gen. Counsel & Joint Company Sec.
Mr. Christian Mueller
Director of Clinical Devel. & Regulatory Affairs
Mr. Shengfei Fang
Fin. Director & Assistant Company Sec.
Mr. Marc Voigt
Chief Executive Officer, MD, Chief Financial Officer, Chief Bus. Officer & Executive Director
Ms. Indira Naidu
Joint Company Sec.
Mr. Florian D. Vogl M.D., M.Sc., Ph.D.
Chief Medical Officer
Dr. Frederic Triebel M.D., Ph.D.
Chief Scientific Officer & Executive Director

How IMMP did perform over past 52-week?

IMMP's closing price is 111.36% higher than its 52-week low of $1.32 where as its distance from 52-week high of $3.53 is -20.96%.

How many employees does IMMP have?

Number of IMMP employees currently stands at 41.

Link for IMMP official website?

Official Website of IMMP is: https://www.immutep.com

How do I contact IMMP?

IMMP could be contacted at phone 612 831 57003 and can also be accessed through its website. IMMP operates from Australia Square, Sydney, NSW 2000, Australia.

How many shares of IMMP are traded daily?

IMMP stock volume for the day was 110.88K shares. The average number of IMMP shares traded daily for last 3 months was 739.72K.

What is the market cap of IMMP currently?

The market value of IMMP currently stands at $410.67M with its latest stock price at $2.79 and 147.19M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	41
Beta	1.69
Sales or Revenue	$5.04M
5Y Sales Change%	-0.802%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

IMMP Company Profile and Key Details

Immutep

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Price Forecast & Outlook

Key Takeaways